Category Archives: Topics

Jardiance outcomes-based contract with Prime Therapeutics

Prime Therapeutics announced it has entered into a Jardiance outcomes-based contract (OBC) with BI as part of the Prime CareCentered Contracting program. According to the press release, Prime will measure outcomes by assessing the overall cost per patient on Jardiance vs “patients taking other diabetic medications.”

This content is for Read Less members only.
Register
Already a member? Log in here

JDRF partners with Korean patch pump manufacturer

JDRF announced a partnership with EOFlow, a South Korean medical device company, to develop a patch pump automated insulin delivery system. EOFlow currently has two diabetes pipeline products including a wearable insulin pump-only (EOPatch) and an artificial pancreas system (EOPancreas).

This content is for Read Less members only.
Register
Already a member? Log in here

Biocon CY Q4 ’17 (FY Q3 ’18) Earnings Update

Biocon hosted its CY Q4 ’17 (FY Q3 ’18) earnings call and provided updates on its insulin portfolio including bs-glargine regulatory status, bs-aspart Ph1 initiation, and Tregopil (oral insulin) Ph2/3 initiation in India. Below are highlights from the call.

This content is for Read Less members only.
Register
Already a member? Log in here

Abbott Q4 ’17 Earnings Update

Abbott hosted its Q4 and full year 2017 earnings updates. Furthermore, Abbott provided an update on its recently launched Libre Consumer. Below are highlights from the call.

This content is for Read Less members only.
Register
Already a member? Log in here

Novartis Q4 ’17 Earnings Update

Novartis hosted its Q4 and full year 2017 earnings updates. Novartis briefly discussed its SGLT1/2i (LIK066), which is being developed for obesity. Of note, Novartis said it anticipates completing their Ph2b trial in H2 ’18 with Ph3 to potentially initiate as early as YE ’18 or early 2019. Below are highlights from the calls.

This content is for Read Less members only.
Register
Already a member? Log in here

J&J Q4 ’17 Earnings Update

J&J hosted their Q4 ’17 earnings call and briefly discussed the diabetes business unit, including declining Invokana sales and the future of their diabetes device business. Notably, in response to analyst questions regarding potential diabetes divestitures, management was noncommittal.

This content is for Read Less members only.
Register
Already a member? Log in here

FENIX Analysis: Bydureon BCise now available

In early January AZ announced the availability of Bydureon BCise autoinjector in US pharmacies after receiving FDA approval in Oct 2017. FENIX has conducted GLP-1RA market, pricing, and co-pay card analyses.

This content is for Read Less members only.
Register
Already a member? Log in here

Sanofi cuts 400 diabetes sales team workers

Sanofi has reportedly announced a round of 400 layoffs for the diabetes and cardiovascular business unit sales team. In a separate news release, it was also announced that Sanofi has appointed Dominique Carouge, former VP of Administration & Management for Global R&D, as a new EVP Head of Business Transformation.

This content is for Read Less members only.
Register
Already a member? Log in here

J&J receives investment bids from Chinese companies

Johnson & Johnson’s diabetes business unit is reportedly being assessed by a number of Chinese investors in a deal which could gross up to $4 billion. Potential bidders are said to include Chinese diabetes care companies such as Sinocare Inc and financial institution China Jianyin Investment Ltd (JIC).

This content is for Read Less members only.
Register
Already a member? Log in here